A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft- versus -host disease: BMT CTN 0801

• Published in: Haematologica (Roma) Vol. 103; no. 11; pp. 1915 - 1924
• Main Authors: Carpenter, Paul A., Logan, Brent R., Lee, Stephanie J., Weisdorf, Daniel J., Johnston, Laura, Costa, Luciano J., Kitko, Carrie L., Bolaños-Meade, Javier, Sarantopoulos, Stefanie, Alousi, Amin M., Abhyankar, Sunil, Waller, Edmund K., Mendizabal, Adam, Zhu, Jiaxi, O’Brien, Kelly A., Lazaryan, Aleksandr, Wu, Juan, Nemecek, Eneida R., Pavletic, Steven Z., Cutler, Corey S., Horowitz, Mary M., Arora, Mukta
• Format: Journal Article
• Language: English
• Published: Italy Ferrata Storti Foundation 01.11.2018
• Subjects: Aged; Calcineurin Inhibitors - administration & dosage; Chronic Disease; Disease-Free Survival; Female; Graft vs Host Disease - mortality; Graft vs Host Disease - therapy; Humans; Male; Middle Aged; Photopheresis; Prednisolone - administration & dosage; Sirolimus - administration & dosage; Survival Rate

Initial therapy of chronic graft- -host disease is prednisone ± a calcineurin-inhibitor, but most patients respond inadequately. In a randomized, adaptive, phase II/III, multicenter trial we studied whether prednisone/sirolimus or prednisone/sirolimus/photopheresis was more effective than prednisone...